Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Lexicon Pharmaceuticals, Inc. (LXRX)

2.8198   -0.21 (-6.94%) 06-09 15:01
Open: 3.02 Pre. Close: 3.03
High: 3.0301 Low: 2.79
Volume: 2,221,359 Market Cap: 690(M)

Technical analysis

as of: 2023-06-09 2:46:10 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 3.83     One year: 4.42
Support: Support1: 2.46    Support2: 2.04
Resistance: Resistance1: 3.28    Resistance2: 3.78
Pivot: 2.93
Moving Average: MA(5): 2.79     MA(20): 2.93
MA(100): 2.51     MA(250): 2.43
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 45.3     %D(3): 36.3
RSI: RSI(14): 49.4
52-week: High: 3.78  Low: 1.3
Average Vol(K): 3-Month: 1,780 (K)  10-Days: 6,375 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ LXRX ] has closed above bottom band by 37.8%. Bollinger Bands are 48.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.12 - 3.13 3.13 - 3.14
Low: 2.8 - 2.81 2.81 - 2.82
Close: 3.01 - 3.03 3.03 - 3.05

Company Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Headline News

Wed, 07 Jun 2023
Is Lexicon Pharmaceuticals Inc (LXRX) a Winner in the Healthcare Sector? - InvestorsObserver

Tue, 06 Jun 2023
Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference - Yahoo Finance

Tue, 06 Jun 2023
Lexicon stock gains after closing equity raise (NASDAQ:LXRX) - Seeking Alpha

Thu, 01 Jun 2023
Healthcare Stocks Moving Thursday: REUN, NNVC, VEEV, CGTX, HOOK, LXRX, KPRX, IVVD - InvestorsObserver

Wed, 31 May 2023
Lexicon Pharmaceuticals Inc (LXRX) has gained 7.84% in a Week, Should You Buy? - InvestorsObserver

Tue, 30 May 2023
HP, Lexicon Pharmaceuticals And 3 Stocks To Watch Heading Into Tuesday - HP (NYSE:HPQ), Box (NYSE:BOX) - Benzinga

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 190 (M)
% Held by Insiders 8.129e+007 (%)
% Held by Institutions 1.1 (%)
Shares Short 4,200 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.0809e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -86
Return on Assets (ttm) 128.5
Return on Equity (ttm) -45.4
Qtrly Rev. Growth 126000
Gross Profit (p.s.) -26.4
Sales Per Share -91.85
EBITDA (p.s.) -3.9609e+007
Qtrly Earnings Growth -0.6
Operating Cash Flow 0 (M)
Levered Free Cash Flow -97 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales -0.04
Price to Cash Flow 8.19

Stock Dividends

Dividend 0
Forward Dividend 6.45e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.